Search: onr:"swepub:oai:lup.lub.lu.se:918ffd12-a1d8-45f8-a58d-78eaf4aeb784" >
Treatment for patie...
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
-
- Dreyling, Martin (author)
- Ludwig-Maximilian University of Munich
-
- Aurer, Igor (author)
- University Hospital Centre Zagreb
-
- Cortelazzo, Sergio (author)
- Humanitas Gavazzeni - Ospedale a Bergamo
-
show more...
-
- Hermine, Olivier (author)
- Paris Descartes University
-
- Hess, Georg (author)
- Johannes-Gutenberg University Mainz
-
- Jerkeman, Mats (author)
- Lund University,Lunds universitet,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,Lymphoma - Clinical Research,Lund University Research Groups
-
- Le Gouill, Steven (author)
- Nantes University Hospital
-
- Ribrag, Vincent (author)
- Institut Gustave Roussy
-
- Trněný, Marek (author)
- Charles University in Prague
-
- Visco, Carlo (author)
- Ospedale San Bortolo
-
- Walewski, Jan (author)
- The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
-
- Zaja, Francesco (author)
- University of Udine
-
- Zinzani, Pier Luigi (author)
- University of Bologna
-
show less...
-
(creator_code:org_t)
- 2017-11-27
- 2018
- English.
-
In: Leukemia and Lymphoma. - : Informa UK Limited. - 1042-8194 .- 1029-2403. ; 59:8, s. 1814-1828
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://www.tandfonl...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalidomide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for, unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Chemotherapy
- clinical trials
- mantle cell lymphoma
- molecular targeted therapy
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Dreyling, Martin
-
Aurer, Igor
-
Cortelazzo, Serg ...
-
Hermine, Olivier
-
Hess, Georg
-
Jerkeman, Mats
-
show more...
-
Le Gouill, Steve ...
-
Ribrag, Vincent
-
Trněný, Marek
-
Visco, Carlo
-
Walewski, Jan
-
Zaja, Francesco
-
Zinzani, Pier Lu ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Leukemia and Lym ...
- By the university
-
Lund University